The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study

American Journal of Kidney Diseases

Volumn 42, Issue 1 SUPPL. 2, 2003, Pages 67-75

  Boero, Roberto ^a   Rollino, Cristiana ^b   Massara, Carlo ^b   Berto, Ilario M ^b   Perosa, Paolo ^b   Vagelli, Giuseppe ^b   Lanfranco, Giacomo ^b   Quarello, Francesco ^b  

^a Divisione di Nefrologia e Dialisi   (Italy)

^b NONE

Author keywords

Angiotensin converting enzyme (ACE) inhibitors; Calcium channel blockers (CCBs); Nephropathies; Proteinuria; Randomized trials

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLONIDINE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FUROSEMIDE; IMMUNOGLOBULIN G; LOSARTAN; NIFEDIPINE; TRANDOLAPRIL; VERAPAMIL;

ADULT; AGED; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; ERECTILE DYSFUNCTION; FEMALE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERKALEMIA; KIDNEY CLEARANCE; KIDNEY DISEASE; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

EID: 0038724678     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-6386(03)00410-4     Document Type: Article

References (28)

1. Ruggenenti P, Perna A, Mosconi L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in nondiabetic proteinuric chronic nephropathies. Kidney Int 53:1209-1216, 1998
2. Peterson JC, Adler S, Burkart JM, et al: Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123:754-762, 1995
3. Maschio G, Alberti D, Janin G, et al: Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939-945, 1996
4. The GISEN Group: Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 349:1857-1863, 1997
5. Jafar TH, Stark PC, Schmid CH, et al: AIPRD Study Group. Angiotensin-Converting Enzyme Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of nondiabetic renal disease. Kidney Int 60:1131-1140, 2001
6. Apperloo AJ, de Zeeuw D, de Jong PE: Short term antiproteinuric response to antihypertensive treatment predicts long term GFR decline in patients with nondiabetic renal disease. Kidney Int Suppl 45:S174-S178, 1994
7. Rossing P, Hommel E, Smodt UM, Parving HH: Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:511-516, 1994
8. Jerums G, Panagiotopoulos S, Tsalamandris C, Allen TJ, Gilbert RE, Comper WD: Why is proteinuria such an important risk factor for progression in clinical trials? Kidney Int Suppl 63:S87-S92, 1997
9. Giatras I, Lau J, Levey AS: Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal diseaseA meta-analysis of randomised trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group. Ann Intern Med 127:337-345, 1997
10. Jafar TH, Schmid CH, Landa M, et al: Angiotensin-converting enzyme inhibitors and progression of non-diabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 135:73-87, 2001
11. Joint National Committee: The Sixth Report of the Joint National Committee on Detection. Evaluation and Treatment of High Blood Pressure (JNC-VI). Arch Intern Med 157:2413-2446, 1977
12. Laing C, Unwin RJ: Are calcium antagonists effective in preventing complications of hypertension and progression of renal disease? Curr Opin Nephrol Hypertens 9:489-495, 2000
13. Ruggenenti P, Perna A, Benini R, Remuzzi G: Effects of dihydropiridine calcium channel blockers, angiotensin converting enzyme inhibition, and blood pressure control on chronic nondiabetic nephropathies. J Am Soc Nephrol 9:2096-2101, 1998
14. Agodoa LY, Appel L, Bakris GL, et al: African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomised controlled trial. JAMA 285:2719-2728, 2001
15. Kloke HJ, Branten AJ, Huysmans FT, Wetzels JF: Antihypertensive treatment of patients with proteinuric renal diseases: Risk or benefits of calcium channel blockers? Kidney Int 53:1559-1573, 1998
16. Bakris GL: Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 112:707-708, 1990
17. Bakris GL, Weir MR, DeQuattro V, McMahon FG: Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 54:1283-1289, 1998
18. Hemmelder MH, de Zeeuw D, de Jong PE: Anti-proteinuric efficacy of verapamil in comparison to trandolapril in nondiabetic renal disease. Nephrol Dial Transplant 14:98-104, 1999
19. Boero R, Rollino C, Massara C, et al: Verapamil versus amlodipine in proteinuric nondiabetic nephropathies treated with trandolapril (VVANNTT study): Design of a prospective randomised multicenter trial. J Nephrol 14:15-18, 2001
20. Herlitz H, Harris K, Risler T, et al: The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: The Nephros Study. Nephrol Dial Transplant 16:2158-2165, 2001
21. Petersen LJ, Petersen JR, Talleruphuus U. et al: A randomised and double-blind comparison of isradipine and spirapril as monotherapy and in combination on the decline in renal function in patients with chronic renal failure and hypertension. Clin Nephrol 55:375-383, 2001
22. The PROCOPA Study Group: Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: A randomised double-blind trial. J Hypertens 20:729-737, 2002
23. Smith AC, Toto R, Bakris GL: Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int 54:889-896, 1998
24. Hartmann A, Lund K, Holdaas H, et al: Contrasting short-term effects of nifedipine on glomerular and tubular functions in glomerulonephritic patients. J Am Soc Nephrol 5:1385-1390, 1994
25. Holdaas H, Hartmann A, Berg KJ, et al: Renal effects of losartan and amlodipine in hypertensive patients with nondiabetic nephropathy. Nephrol Dial Transplant 13:3096-3102, 1998
26. Bazzi C, Petrini C, Rizza V, et al: A modem approach to selectivity of proteinuria and tubulointerstitial damage in nephrotic syndrome. Kidney Int 58:1732-1741, 2000
27. Bakoush O, Torffvit O, Rippe B, Tencer J: High proteinuria selectivity index based upon IgM is a strong predictor of poor renal survival in glomerular diseases. Nephrol Dial Transplant 16:1357-1363, 2001
28. Russo LM, Bakris GL, Comper WD: Renal handling of albumin: A critical review of basic concepts and perspective. Am J Kidney Dis 39:899-919, 2002